The relationship between autoimmunity and HbA1c in type 1

Key Findings & Data:Islet cell antibody (ICA), insulin autoantibody (IAA), glutamic acid decarboxylase enzyme antibody (GADA) and HgA1c are also used in the diagnosis and follow-up of patients with type 1 diabetes mellitus.

💡

Conclusion & Impact:Antibody selection according to age during diabetes screening was found to be significant in terms of cost.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Indicators of increased risk for type 1 diabetes (T1DM) are specific antibodies that are mainly immune markers. Islet cell antibody (ICA), insulin autoantibody (IAA), glutamic acid decarboxylase enzyme antibody (GADA) and HgA1c are also used in the diagnosis and follow-up of patients with type 1 diabetes mellitus. ICA, IAA, GADA, HbA1c were checked at the time of diagnosis and at 6-month intervals in pediatric patients monitored with T1DM. Decreased ICA, GADA and HbA1c levels were evaluated as good blood glucose control and good clinical response. Patients aged ≤5 years had a higher rate of IAA and patients aged >5 years had a higher rate of ICA. Antibody selection according to age during diabetes screening was found to be significant in terms of cost.

🔖

Cite This Article

Akinci, A., Dundar, I., Ates, D. C. (2022). The relationship between autoimmunity and HbA1c in type 1. Medicine Science, Cilt: 10 - Sayı: 4, 1505–1509. https://ajindex.com/articles/579751

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (16)

Ishii M, Hasegavva G, Fukui M, et al. Clinical and genetik characteristic of diabetic patients with high-titer(>10000 U/ml) of antibodies to glutamic acid decarboxylase. Immunol Lett. 2005;99:180-5
Kupila A, Keskinen P, Simell T, et al. Genetic risk determines the emergence of diabetes-associated autoantibodies in young children. Diabetes. 2002;51:646-51
Borg H, Marcus C, Sjöblad S, et al. Insulin autoantibodies are of less value compared with islet antibodies in the clinical diagnosis of autoimmune type 1 diabetes in children older than 3 yr of age. Pediatr Diabetes. 2002;3:149- 54
Chang YH, Shiau MY, Tsai ST, et al. Autoantibodies against IA-2, GAD, and topoisomerase II in type 1 diabetic patients. Biochem Biophys Res Commun. 2004;320:802-9
Isermann B, Ritsal R, Zorn M, et al. Autoantibodies in diabetes mellitus: current utility and perspectives. Exp Clin Endocrinol Diabetes. 2007;115:483-90
Lifshitz F. Pediatric Endocrinology. Fourth edition. 2003;28:683-720
Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ. 2004;328:750-4
Atkinson MA, McLaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med. 1994;331:1428-36
Stene LC, Magnus P, Lie RT, et al. The Norwegian childhood Diabetes Study Group. Birth weight and childhood onset type 1 diabetes: population based cohort study. BMJ. 2001;322:889-92
Bosi E, Sarugeri E. Advances and controversies in etiopathogenesis of type 1 (insulin- dependent) diabetes mellitus. J Pediatr Endocrinol Metab. 1998;2:293-305
Dahlquist G.The etiology of type 1 diabetes. An epidemiological perspective. Açta Paediatr. 1998;425:5-10
Colman PG, Steele C, Couper JJ, et al. Islet autoimmunity in infants with a type 1 diabetic relative is common but is frequently restricted to one autoantibody. Diabetologia. 2000;43:203-9
Maugendre D, Sonnet E, Derrien C, et al. Combined analysis of long-term anti-beta-cell humoral reactivity in type 1 diabetes with and without thyroid disease. Diabetes Metab. 1999;25:28-33
WasserfalI CH and Atkinson MA. Autoimmunity Revievvs. 2006;6:424-8
Arnold JG, McGovvan HJ. Delay in diagnosis of diabetes mellitus due to inaccurate use of hemoglobin A1c levels. J American Board. 2007;20:93-6
The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977-86